PhotoCure - Licensing deal with GE Healthcare for bladder cancer
GE Healthcare and PhotoCure announce licensing partnership for the optical imaging of bladder cancer.OSLO, NORWAY - JANUARY 6, 2006 - GE Healthcare, a unit of General Electric Company (NYSE: GE) and PhotoCure ASA (OSE: PHO), today announced a licensing agreement that grants GE Healthcare exclusive global rights outside of the US and the Nordic region to market and distribute PhotoCure's product Hexvix® (hexaminolevulinate), an optical molecular imaging agent intended for the diagnosis and monitoring of bladder cancer. The agreement includes total milestones of MEUR 28, of which MEUR 7 at